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ABSTRACT
THE EFFECTS OF INDUCED POLYCYSTIC OVARY
SYNDROME IN NAG-1 TRANSGENIC MICE
by
Nicholas James Werner
June 2020

Polycystic ovary syndrome (PCOS) is the leading cause of infertility among
women in the US and the most common endocrine disorder among women. PCOS is
characterized by cystic ovaries, hyperandrogenism (heightened levels of male sex
hormones), altered menstrual cycles and various metabolic dysfunctions. The
metabolic symptoms associated with PCOS are difficult to treat, as they are a result
of hormonal imbalances, rather than diet. The human Non-Steroidal AntiInflammatory Drug Activated Gene (NAG-1) been shown to prevent diet-induced
metabolic disorders and weight gain in mice. We hypothesized that the expression
of NAG-1 may also prevent hormonal-induced metabolic disorders. To test this
question, we induced PCOS via dihydrotestosterone (DHT) implantation in
transgenic mice expressing the human NAG-1 gene. Our findings suggest that NAG-1
mice have similar physiological responses to DHT-treatment as compared to wildtype mice throughout the 90-day study. Specifically no changes in the age of puberty
and anal-genital distance (AGD) were observed. NAG-1 mice also display similar
ovarian phenotypes, developing fewer corpora lutea, and having disrupted estrus
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cycles. NAG-1 mice displayed no significant weight gain between treatment groups
throughout the study, and no significant increase in triglyceride levels. Additionally,
NAG-1 mice showed no change in white adipocyte morphology after DHT-treatment.
However, wild-type mice treated with DHT showed an increased amount of brown
adipocytes differentiating to white adipocytes, compared to NAG-1 mice. Our
findings indicate that NAG-1 mice respond similarly to DHT-treatment as wild-type
mice in ovarian response, but continue to maintain their lean phenotype in the
presence of induced PCOS. These findings suggest that expression of NAG-1 may
have therapeutic benefits in the prevention of hormonal induced weight gain, and
brown adipocyte hypertrophy.
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CHAPTER I
INTRODUCTION AND LITERATURE REVIEW
Sexual reproduction is the result of the fusion between the male and female
gametes, known as the sperm and the oocyte, respectively. In males, the gametes are
produced in the testis through a process known as spermatogenesis, while in the
females they are produced in the ovary through oogenesis. Males begin to produce
sperm at puberty and continue throughout their life, while females are born with a
fixed number of oocytes, produced during fetal development. In order to ensure
reproductive success, the ovary must be highly efficient at maintaining the gametes
and ensuring their proper growth and release throughout the female’s reproductive
lifespan. Occasionally, ovarian homeostasis may become impaired, and interrupt
this process. One way ovarian homeostasis can become impaired is as the result of
increased levels of androgens [1]. This elevated level of androgens is a condition
known as hyperandrogenism. Hyperandrogenism in females can lead to infertility,
formation of ovarian cysts, and irregularities in estrus or menstrual cycles [2]. In
addition to these ovarian phenotypes, hyperandrogenism can also contribute to
several types of metabolic disorders. The combination of hyperandrogenism,
ovarian dysfunction, and an impaired metabolic phenotype culminate in a disease
called polycystic ovary syndrome (PCOS). Common metabolic disorders associated
with PCOS include glucose intolerance, type-II diabetes, obesity, and fatty liver
disease [3]. Because these metabolic disorders arise as a result of hormonal
imbalances, and not diet, they can prove difficult to treat. To understand changes in
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ovarian homeostasis, and how they can lead to metabolic disorders, it is important
to know the signaling processes that regulate ovarian function.
The Ovary
The ovary is the site of oogenesis and the synthesis of reproductive steroid
hormone production in the female. It is here that the oocyte will receive nutrients,
mature, and be released into the fallopian tube for fertilization beginning at puberty
[4]. Due to its vital role in reproduction, the ovary is comprised of many different
specialized cells that are responsible for maintaining the homeostasis of certain
steroid hormones that ensures the oocytes develop correctly and are released at the
appropriate time. Maintenance and production of these hormones occurs in
structures within the ovary called follicles.
The Mechanism of Follicular Development
The oocyte is stored, undergoes development and maturation in a circular
structure known as an ovarian follicle. The follicle is also responsible for producing
testosterone, estrogen and progesterone in response to the release of follicle
stimulating hormone (FSH) and luteinizing hormone (LH). FSH and LH released
from the pituitary gland are responsible for ensuring proper growth and
development of the oocyte, as well as the proper timing of its release into the
fallopian tubes (ovulation) for fertilization. LH is responsible for the ovulation of the
oocyte, initiating the synthesis of testosterone, and progesterone that prepares the
endometrium for implantation of the fertilized oocyte [5, 6, 7].
The three main cell types of the ovarian follicle are theca cells, granulosa
cells, and the oocyte [8]. The oocyte is located in the center of the follicle, where it
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will grow and mature in a process called oogenesis. As the oocyte matures, the
follicle undergoes transformation in a process called folliculogenesis. The earliest
stage of a follicle is known as a primordial follicle and is comprised of an oocyte
surrounded by several flat granulosa cells [9]. Folliculogenesis is initiated by the
release of FSH from the pituitary gland. FSH binds to its specific G-protein coupled
receptor, which stimulates intracellular signaling leading to increased granulosa cell
division resulting in an increasingly thick layer of granulosa cells, while the oocyte
forms a zona pellucida [9]. At this stage in development, the follicle is referred to as
a primary follicle. The follicle then recruits a thin layer of theca cells, and develops
into a secondary follicle. Theca cells form the outermost layer of the ovarian follicle,
and are primarily responsible for the production of male sex hormones (androgens)
[10]. The primary androgen produced is androstenedione, which is a precursor to
estradiol [11]. The theca cells express the luteinizing hormone receptor (LHR) and
synthesize androgens in response to LH secreted from the pituitary. This leads to
increased expression of Lhr/LHR on both the granulosa and theca cells as the follicle
grows [5]. High levels of vascular endothelial growth factor mRNA have also been
observed in theca cells, suggesting they may have a role in vascularization [12].
The release of the mature oocyte, known as ovulation, is triggered by a surge
of LH from the pituitary [5]. After ovulation the follicle differentiates into a
progesterone producing structure called the corpus luteum, and will regress back
into the ovary as scar tissue [13]. The ovary can have multiple stages of
folliculogenesis occurring at any given time in order to assure an oocyte is released
on a regular basis. As a mature follicle is preparing to ovulate its oocyte, there may
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be corpus lutea, as well as immature follicles present in the ovary. In humans, an
oocyte will be ovulated approximately once a month, and the entire process of
folliculogenesis takes roughly 300 days [14]. In contrast, mice may release multiple
oocytes once every four to five days, and a complete round of folliculogenesis takes
only 19 days [15]. Although there are differences in the timing of folliculogenesis
and ovulation, mice go through folliculogenesis physiologically and biochemically
similar to humans making them an ideal model for studying ovarian function.
Follicular Hormone Signaling
The hypothalamic-pituitary-gonadal (HPG) axis is responsible for the
regulation of development and reproduction in animals and thus plays a critical role
in maintaining a healthy ovary and normal reproductive function [16]. The
hypothalamus is composed of hypothalamic neurons, and is responsible for the
initiation of hormonal signaling cascade involved in the HPG axis. The
hypothalamus signals directly to the pituitary gland, which is located at the base of
the brain. Signals from the pituitary are released into the bloodstream and travel to
the gonads, which in turn can upregulate or downregulate further signaling from the
hypothalamus or pituitary [17].
In adolescence, the HPG axis remains inactive, but during puberty the ovaries
begin to synthesize and release estrogen in response to LH and FSH secreted by the
pituitary, which in turn activates the HPG axis. As the HPG axis is activated, it begins
releasing gonadotropin-releasing hormone (GnRH) from the hypothalamus to the
pituitary gland [6]. GnRH binds to its G-protein coupled receptor and signals the
gonadotrope cells in the anterior pituitary to release FSH and LH (Fig. 1). The HPG
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axis remains active until menopause in females, when oocytes are depleted and the
ovary stops secreting large amounts of estrogen due to lack of follicular granulosa
cells [16].
FSH is responsible for the growth and maturation of immature small antral
follicles [7]. As pulses of FSH in the ovary drive the growth of follicles, the granulosa
cells begin to produce CYP19A1 (aromatase), which converts androstenedione
produced in the theca cells into estradiol. The estradiol from the granulosa cells
inhibits the production of both GnRH in the hypothalamus and FSH in the pituitary
[18]. This dual inhibition triggers a surge in LH, which in turn triggers the rupturing
of the preovulatory follicle, and the oocyte is ovulated into the fallopian tube for
potential fertilization. After the oocyte is released, the remaining granulosa cells
become luteinized and form a corpus luteum that synthesizes and secretes large
amounts of progesterone and a small amount of estrogen [19, 20]. Estrogen initiates
and maintains cell proliferation in the endometrium prior to the release of the
oocyte, and progesterone prepares the endometrium for possible implantation if
fertilization occurs [21]. Progesterone stimulates the endometrium to enter a
secretory phase, where the inner lining can serve as an implantation site for a
blastocyst [22]. Progesterone also inhibits the hypothalamus from releasing GnRH
to the pituitary [23]. If fertilization does not occur, progesterone levels lower to
basal levels, the corpus luteum regresses back into the ovary, the release of GnRH
will no longer be inhibited, and folliculogenesis can continue [24]. Figure 1
illustrates the pathways through which the HPG axis regulates folliculogenesis.
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These cumulative events mark the completion of one round of folliculogenesis in the
ovary.

Figure 1: Hormonal regulation of folliculogenesis via the HPG axis. The
hypothalamus releases GnRH which signals the anterior pituitary to produce LH and FSH.
FSH promotes recruitment of early follicles and follicular development. Mature follicles
secrete estradiol, which inhibits FSH and GnRH, thus causing a surge in LH. This surge
triggers ovulation and the development of the corpus luteum. The corpus luteum produces
high levels of progesterone, and will eventually regress into the ovary if oocyte is not
fertilized.

Hyperandrogenism in the Ovary
Hormonal signaling in the ovary is tightly regulated by the HPG axis to assure
proper follicular development and ovarian health. The HPG axis is also selfregulating, as it cycles between releasing FSH an LH in response to estrogen and
progesterone production as a result of ovulation. As testosterone is the precursor to
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estrogen synthesis in the ovary, it has the potential to have highly detrimental
effects on ovarian health if dysregulated.
The dysregulation in ovarian androgens begins with the overproduction of
LH from the pituitary. High circulating levels of LH cause an upregulated synthesis
of testosterone, and dihydroepiandrosterone, another common androgen [25].
These androgens are produced by theca cells in the ovary, and under normal
conditions, most are converted to estrogen by the granulosa cells via the enzyme
aromatase [13]. This excess of androgens causes the arrest of follicular
development, and also impairs the function of aromatase [26]. The impaired
aromatase function in turn prevents estrogen production. The arrest of follicular
development causes an increase in anti-mullerian hormone, which inhibits follicular
recruitment and the formation of primary follicles [26]. When follicles become
arrested in development, they can no longer release their oocytes, and may continue
to swell until becoming cystic.
While excess testosterone may cause follicular arrest, small amounts of
testosterone is necessary for maintaining ovarian health. Testosterone has been
shown to promote follicular growth in mice, and may act as a regulator of
progesterone secretion in granulosa cells [27, 28]. While most androgens will be
converted to estrogen and progesterone, androgens alone are necessary for healthy
ovarian and follicular development. Testosterone, DHT, and DHEA bind to the
androgen receptor, and androgen receptor knockout mice have been shown to have
decreased fertility, irregular estrus cycles, and decreased litter sizes [29]. The
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mechanisms for these changes are unknown, but it appears that androgens are
crucial for ovarian function.
Causes for hyperandrogenism has been attributed to hyperinsulinemia, and
overactive adrenal glands [30, 31], but the most prominent theory is that
hyperandrogenism in females arises from the ovary [1]. The high levels of
circulating androgens in combination with cystic ovaries are two key criteria in
diagnosing the endocrine disorder known as polycystic ovary syndrome.
Polycystic Ovary Syndrome
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder
among women of reproductive age, and is estimated to affect between 6 to 14% of
women, depending on which diagnostic criteria is used [32]. The symptoms of PCOS
can manifest themselves with a wide range of variation among affected individuals,
so to avoid over diagnosis, the Rotterdam Criteria was established. These criteria
focus on the most common symptoms of PCOS [4]. Under the Rotterdam Criteria,
and individual can be diagnosed with PCOS by displaying 2 of 3 symptoms: presence
of ovarian cysts, oligo/anovulation, and/ or hyperandrogenism (clinical or
biochemical) [33]. Ovarian cysts are examined via ultrasound [34]. Oligovulation is
defined as irregular menstrual cycles, or having fewer than 8 menstrual cycles per
year in humans [35]. The most common clinical feature of hyperandrogenism is
hirsutism, or the abnormal growth of hair on the face or body [36]. Clinical analysis
of serum in blood samples is also performed to determine serum androgen levels.
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Ovarian Phenotypes Associated With PCOS
An ovarian cyst is formed when a follicle fails to rupture and ovulate its
oocyte, due to the interruption of folliculogenesis. The interruption of
folliculogenesis may stem from several causes, but the most common cause is the
release of excessive LH, which ultimately can lead to the formation of cysts [37]. The
binding of LH to LHR on the theca cells, leads to the synthesis of testosterone, and
the resulting surplus of testosterone from LH leads to high levels of estrogen and
progesterone conversion in the granulosa cells [25]. The level of estrogen from the
ovary causes the secretion of FSH, thus driving the growth of immature follicles [7].
The high levels of FSH also inhibits a process known as follicular atresia, where
granulosa cells undergo apoptosis [38]. In healthy individuals, the majority of
follicles do not rupture; they instead undergo atresia, and are broken down [39]. In
individuals with PCOS, the follicles may not undergo atresia for an extended period
of time (or at all) and will continue to grow, giving them a cyst-like appearance. The
follicle may eventually undergo atresia, or the oocyte may undergo necrosis [40].
Due to the nature of folliculogenesis multiple immature follicles will be maturing at
any given time, so as a cyst regresses, another cyst may take its place [14].
Therefore, it is believed that high levels of LH, testosterone, or a combination of the
two are responsible for the formation of ovarian cysts commonly observed in PCOS.

Prevalence of Infertility, and Effects on Mental Health
In an unselected US population, up to 72% of individuals with PCOS reported
infertility, in comparison to 16% in those without PCOS [41]. The mental health of
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those with PCOS may be impacted as well. Those with PCOS report higher levels of
depression and anxiety than unaffected individuals, regardless of age [42].
Symptoms of PCOS such as obesity and hirsutism may be contributing factors to the
poor mental wellbeing of affected individuals, and can contribute to the worsening
quality of life reported by these individuals [43].

Metabolic Disorders Associated With PCOS
While ovarian phenotypes and hyperandrogenism provide a partial
diagnostic criterion, there exists a myriad of metabolic disorders associated with
PCOS, including obesity and type-II diabetes [44]. Women with PCOS are also at a
higher risk for development of insulin resistance and non-alcoholic fatty liver
disease [45]. It is estimated that PCOS-related obesity affects up to 42% of those
with PCOS [46]. Despite being a prevalent feature of the disease, obesity is not
universal among those with PCOS, and may not be present in some individuals. The
insulin resistance in women with PCOS may be present regardless of if the affected
individual is obese, and is estimated to be present in 50-90% of PCOS patients [47,
48].

PCOS-Associated Metabolic Disorders
Insulin resistance is a common disorder associated with PCOS, and its
presence may contribute to the severity of the disease [49]. In healthy individuals,
insulin is secreted in response to an increase in blood glucose, and signals for cells
in the body to uptake and store glucose, as well as initiating the conversion of
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glucose to other metabolite such as DNA, lipids, and proteins [50]. Insulin functions
by binding to the insulin receptor, which initiates a signal cascade causing glucose
transporter type 4 (GLUT-4) transporters to translocate to the cell membrane,
where glucose can then be taken into the cell [50]. When an individual suffers from
insulin resistance, their cells have an impaired ability to intake glucose due to a
decreased cellular response to insulin. To compensate, the pancreas begins
secreting more insulin [51]. Increased insulin levels stimulate the production of
Insulin-Like Growth Factor 1 (IGF1), which has been shown to increase the
secretion of androgen from theca cells [52].
Other common metabolic symptoms of PCOS that may contribute to glucose
intolerance include obesity, dyslipidemia, and hypertension [53]. As glucose
intolerance becomes more severe, it can also contribute to the exacerbation of these
symptoms [53]. An increase in adipose tissue due to glucose intolerance and weight
gain can damage the beta islet cells of the pancreas, lowering insulin production.
This decrease in insulin production can lead to the development of type-II diabetes
[54]. Serum levels of triglycerides and cholesterol in those with PCOS also tend to
be higher [53, 55]. All of these symptoms can be lumped together into another
condition known as metabolic syndrome, which is not specific to PCOS, but is
characterized by the metabolic symptoms seen in PCOS [55]. The metabolic aspects
of PCOS are difficult to treat, as they are a result of the hormonal irregularities
associated with the disease, and not due to diet. As diet and lifestyle alterations
alone may not be enough to curb the symptoms in affected individuals, researchers
are investigating alternative ways of treating these disorders in PCOS.
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Dihydrotestosterone-Induced PCOS
Several rodent models of PCOS currently exist, which mimic many of the
symptoms of the PCOS phenotypes observed in humans. These models are
generated either by pre- or post-natal introduction of exogenous androgens, or
aromatase inhibitors to prevent the conversion of testosterone to estrogen and
progesterone [3]. Dihydrotestosterone (DHT) is an androgen functionally similar to
testosterone, and can bind to the androgen receptor and regulate androgen
dependent gene transcription [56]. DHT differs from testosterone in that it cannot
be converted to estrogen or progesterone, which makes it an excellent molecule to
induce hyperandrogenism (a key feature of PCOS) in female mice without
confounding effects due to estrogen conversion. Treating pre-pubescent mice with
7.5 mg of extended release DHT over 90 days has been shown to induce the major
symptoms of PCOS including obesity, impaired glucose tolerance, irregular estrus
cycles, and cystic ovaries [2]. DHT- treatment in mice has also been shown to induce
adipocyte hypertrophy, dyslipidemia, and hepatic steatosis [3]. Given DHT’s ability
to reproduce many key human features of PCOS, it has been used to create a mouse
model of PCOS that allows for the study of both the ovarian and metabolic
components of the disease.

Transgenic NAG-1 Have a Lean Phenotype
The Non-Steroidal Anti-Inflammatory Drug Activated Gene (NAG-1), also
known as macrophage inhibitory cytokine 1(MIC-1) or growth differentiation factor
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15 (GDF15), belongs to the transforming growth factor beta family of genes [57].
NAG-1 is present in low levels in many central organs, and can reduce inflammation
responses when upregulated [58]. While the function of NAG-1 is unknown, it
appears to play a role in body weight and regulation of thermogenesis in mice [59].
Transgenic mice overexpressing the human NAG-1 gene weigh significantly less and
have lower levels of white adipose tissue compared to their wild-type littermates
[60]. Transgenic NAG-1 mice are more metabolically active, have greater lean body
mass, and consume less food than wild-type mice [60]. Transgenic NAG-1 mice also
have improved glucose tolerance and insulin production in both males and females,
regardless of diet, as well as increased thermogenesis-related gene expression in
brown adipose tissue [59]. When a glucose tolerance test is performed after a 12hour fasting period, NAG-1 mice have been shown to have a much lower spike in
initial glucose uptake, and also return to a basal level more quickly than wild-type
mice. When the same mice are injected with insulin, the NAG-1 mice also show a
larger drop in blood glucose levels, suggesting that expression of NAG-1 improves
glucose tolerance [61]. Mice expressing NAG-1 also have an increased amount of
brown adipose tissue and a reduced amount of white adipose tissue [61].
Several thermogenesis genes are upregulated in brown adipose tissue in
NAG-1 mice, including uncoupling protein 1 (UCP1), peroxisome proliferatoractivated receptor gamma coactivator 1-alpha (PGC1a), cytochrome c oxidase
subunit 8B (COX8B), and peroxisome proliferator-activated receptor alpha (PPARa),
which when upregulated, lead to greater heat production from metabolic processes
[59]. UCP1 is a proton uncoupler, and decreases the proton gradient in oxidative
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phosphorylation [62]. This decrease in the proton gradient results in the
mitochondria producing less ATP, and more heat [62]. PGC1a is a regulator of
energy metabolism, and controls the growth of mitochondria [63]. COX8B codes for
a subunit of the final electron acceptor in oxidative phosphorylation, and its
upregulation is linked to higher metabolic activity [64]. PPARa is a transcription
factor, and is responsible for regulating lipid metabolism, and fatty acid oxidation in
the mitochondria [65]. The increase in heat production from the up regulation of
these genes may play a role in the development of the lean phenotype observed in
NAG-1 mice and the resistance to diet induced weight gain.
These alterations to metabolism, weight, and thermogenesis regulation occur
regardless of whether or not mice are fed a high-fat diet [61]. To date, current
studies on NAG-1 and its role in metabolism regulation only focus on diet-induced
metabolic dysfunctions, while the metabolic dysfunctions seen in PCOS are a result
of hormone dysregulation. This presents a novel opportunity to study the effects of
hormonally induced metabolic disorders, specifically those due to PCOS, on
transgenic NAG-1 mice.
Conclusions
PCOS is a dynamic disease. Based on the name alone, one would surmise that
the disease is localized to the ovary, but its symptoms may affect a variety of organs.
The primary way PCOS affects the body outside of the ovary and reproductive
system is by causing or contributing to many detrimental metabolic disorders. As
the metabolic disorders associated with PCOS are a result of hormonal imbalances,
they become difficult to treat. The NAG-1 mice provide a unique model to explore
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differences in diet versus hormonal induced metabolic disorder. When on a high-fat
diet, mice expressing NAG-1 have been shown have a lean phenotype, and also have
resistance to the same metabolic disorders seen in PCOS. However, the mechanism
behind how NAG-1 can lead to this phenotype and resistance is unknown. As we
induce these metabolic disorders through a mouse model of PCOS, we hypothesize
that NAG-1 will continue to protect the mice from metabolic disorders, even when
they are hormonally induced, due to its efficiency at protecting against the same
disorders when diet induced.
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Abstract
Polycystic ovary syndrome (PCOS), a leading cause of infertility in women, is
a dynamic disease characterized by cystic ovaries, hyperandrogenism, altered
menstrual cycles and metabolic dysfunction. As the metabolic disorders present in
PCOS are caused as a result of hormonal dysfunction, they can be difficult to treat.
Understanding the underlying cellular mechanisms and genes involved in metabolic
disorders may lead to novel therapeutic approaches. The human Non-Steroidal AntiInflammatory Drug Activated Gene (NAG-1) also known as GDF15 has been shown
to prevent diet-induced metabolic disorders when overexpressed in transgenic
mice. NAG-1 transgenic mice have a lean phenotype, and resistance to development
of metabolic disorders when on a high-fat diet. We hypothesized that NAG-1 mice
would maintain this lean phenotype in response DHT-induced PCOS. Our findings
indicate that transgenic NAG-1 mice treated with DHT have similar ovarian
responses to wild-type mice but enter puberty earlier than placebo-treated
littermates. NAG-1 DHT-treated mice also display similar ovarian phenotypes to
wild-type DHT-treated mice with disrupted estrus cycles and reduced numbers of
corpus lutea in the ovary. These results suggest NAG-1 mice have a similar ovarian
response to DHT as wild-type mice. We next examined changes in metabolism in
DHT-treated NAG-1 mice. NAG-1 mice displayed no significant weight gain between
treatment groups and no significant increase in triglyceride levels. NAG-1 mice
showed no change in white adipocyte morphology or differentiation from brown
adipocytes into white adipocytes after DHT-treatment in contrast to wild-type mice
treated with DHT. Our findings indicate that NAG-1 mice have similar ovarian
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responses to DHT-treatment as wild-type mice, but continue to maintain their lean
phenotype over wild-type mice in the presence of DHT-induced hyperandrogenism.
Our results suggest that the overexpression of NAG-1 may have therapeutic
potential in preventing some hormonal induced metabolic disorders.
Introduction
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder
among women worldwide affecting 8-14% of the population, and is characterized by
symptoms such as ovarian cysts, hyperandrogenism, and development of metabolic
disorders [1, 2]. The presence of two out of three of the aforementioned symptoms
are required under the Rotterdam diagnostic criteria for the diagnosis [3]. While not
all individuals with PCOS may exhibit metabolic disorders, roughly 90% of the
affected population has some level of metabolic disruption [4, 5]. The metabolic
symptoms can include obesity, type-II diabetes, and fatty liver disease [6]. These
metabolic symptoms are believed to be a result of hyperandrogenism associated
with PCOS, and therefore can be challenging to treat.
Evidence suggests these metabolic symptoms are due to altered levels of
androgen hormones [7]. Ovarian theca cells produce androgens that are converted
to estrogen by aromatase (Cyp19a1) expressed in ovarian granulosa cells [8]. In
women with PCOS, there appears to be an excess of androgen production, coupled
with a lack of conversion of androgens to estrogen due to reduced expression of
aromatase [9]. This condition known as hyperandrogenism can have widespread
effects on the body including development of both reproductive and metabolic
phenotypes. The reproductive phenotypes may include ovarian cysts, irregular
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estrus or menstrual cycles, and infertility [10]. The metabolic aspects of the disease
include obesity, glucose intolerance, type-II diabetes, and fatty liver disease [3].
These phenotypes caused by hyperandrogenism also serve as key diagnostic criteria
for PCOS.
There are several mouse models for studying metabolic disorders, which
include inducing metabolic disorders via being fed on a high-fat diet, or the use of
transgenic or knockout mice that display altered metabolic responses. Transgenic
mice that overexpress the human Non-Steroidal Anti-Inflammatory Drug Activated
Gene (NAG-1) have been shown to be resistant to development of diet-induced
metabolic disorders [11, 12, 13]. These transgenic mice when fed a high-fat diet do
not become obese or suffer any insulin resistance, are more metabolically active
than wild-type littermates, and have reduced levels of white adipose tissue [11]. It is
hypothesized that the transgenic mice’s lean phenotype is due to a significant upregulation of genes involved in thermogenesis [11]. Implanting mice with a
subcutaneous Dihydrotestosterone (DHT) pellet results in the mice displaying
ovarian, hormonal, and metabolic phenotypes similar to those seen in humans with
PCOS [14]. In this study we examined the metabolic response of NAG-1 mice in a
PCOS model induced via DHT implantation.
Transgenic NAG-1 and wild-type mice were treated with placebo or DHT
pellets for 90 days. NAG-1 mice were found to be resistant to weight gain and both
white and brown adipocyte hypertrophy. In contrast, NAG-1 mice exhibited similar
ovarian phenotypes to wild-type mice when exposed to DHT. This study suggests
that NAG-1 mice are resistant to hormonal-induced weight gain, brown adipocyte
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hypertrophy, and have some resistance to white adipocyte hypertrophy. NAG-1
overexpression also appears to have no impact on the ovarian phenotype of DHTinduced PCOS.

Materials and Methods
DHT-Treated Mice
Male transgenic C57BL/6 mice expressing the human NAG-1 gene were
obtained from Dr. Tom Eling at the National Institute of Environmental Health
Sciences and bred at Central Washington University. The transgenic line was
maintained by breeding male NAG-1 mice to wild-type C57BL/6 females. Mice were
fed Mazuri Rat and Mouse Diet ad libitum and kept on a 12-hour light/dark cycle. At
weaning mice were genotyped as previously described [15], and 31 female mice
divided into groups based on genotype (16 wild-type and 15 NAG-1). Mice were
then randomly placed into groups to receive either placebo (wild-type n = 8, NAG-1
n = 8) or DHT (wild-type n = 8, NAG-1 n = 7) implants. Between 23-25 days of age,
mice received a subcutaneous beeswax-based pellet containing either 7.5 mg of
sesame oil or 7.5 mg of DHT (5a-Androstan-17B-ol-3-one, A8380, Sigma-Aldrich
Corp., St. Louis, MO). Pellets were made using a modified protocol published by
Leonie, E., et al. [14]. Modifications made to the protocol include the use of beeswax
(243221, Sigma-Aldrich Corp., St. Louis, MO) as a medium for the pellets, and the
use of 7.5 mg of DHT in place of 2.5 mg. At 90 days post-implantation, the distance
between the anus and genitalia were recorded using a digital caliper. The protocols
for all procedures performed on mice was approved by the Central Washington
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University Institutional Animal Care and Use Committee (Protocol #A101801 and
#A101602).

Body Weights and Glucose Tolerance
Animals were monitored daily and body weights were measured weekly for
the duration of the study.
At 111 days of age (90 days post-implantation) mice had their fasting blood
glucose measured. Mice were fasted 12 hours, and glucose levels were measured
using a glucometer and glucose test strips (ATC Medical, Germantown, TN).
Afterwards, mice were injected intraperitoneally with 2000 mg/kg of dextrose
(Sigma-Aldrich Corp., St. Louis, MO). Blood glucose measurements were taken from
tail snips at 20, 40, 60, 120, and 180 minutes post injection.

Tissue Collection
At the end of the study, mice were euthanized via CO2 inhalation followed by
cervical dislocation as a secondary method. Immediately post-euthanasia, the final
weight of the mice was determined and cardiac puncture was performed to collect
serum samples. Ovaries, white adipose tissue, and brown adipose tissue were
collected and part of the sample was prepared for histological examination using
standard procedures while the remainder was stored at -80° C for gene expression
analysis.
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Measuring Reproductive Development
Vaginal openings were monitored in each treatment group as an assessment
of the onset of puberty. Mice from each group were visually inspected once daily
and the date of vaginal opening was recorded. Ten weeks post-implantation we
performed estrus cycle monitoring for 14 consecutive days. Each morning, saline
solution was used to wash the vagina of each mouse individually. The washes from
each mouse were fixed on glass slides and stained using hematoxylin and eosin
(Sigma-Aldrich Corp., St. Louis, MO), dehydrated and sealed with a glass coverslip.
Estrus cycles were assessed from the slides based on inspection via light microscopy
of cell count and presence of nucleated cells [16]. Slides were analyzed separately by
two individuals and categorized as being predominantly proestrus, estrus,
metestrus, or diestrus. Proestrus slides were defined as having a mixture of
nucleated and anucleated cells, estrus slides as having no nucleated cells, metestrus
slides as having a mixture of nucleated and anucleated cells, as well as leukocytes,
and diestrus slides as having extremely few cells of any kind in comparison to the
other types.

Histology
Tissues were fixed in 10% formalin immediately after collection, and stored
until further use at -4° C. Tissues were then dehydrated through a series of ethanol
washes, and cleared with Citrisolv (Sigma-Aldrich Corp., St. Louis, MO) and
embedded in blocks of paraffin wax. Tissues were sectioned in 8 uM slices, stained
following standard H&E protocols and coverslipped. Images were taken using an
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EVOS XL Microscope. One section of each type of adipose tissue was selected and
used for analysis for each mouse. The area of white adipocytes was measured using
the Watershed Algorithm package on ImageJ. Using the smallest measured white
adipocyte as reference (90 um2), the brown adipose tissue was analyzed using the
Watershed Algorithm for any adipocytes that passed this threshold, which were
classified as enlarged adipocytes. To examine ovarian follicles, ovaries were
sectioned and every 10th section (totaling 5 sections per mouse) was used for
analysis. Only follicles with oocytes present were counted and categorized into five
stages of development: small preantral (1-2 layers of granulosa cells), large
preantral (3-5 layers of granulosa cells), small antral (5+ layers of granulosa cells),
large antral (formation of an antrum), and corpora lutea (large mass of luteinized
cells).

Measuring lipid levels
ELISA reagents were prepared in accordance to the protocols provided in the
Aviva Systems triglyceride (OKEH02597) and cholesterol (OKEH02598) kits (Aviva
Systems Biology Corporation, San Diego, CA). Triglyceride and Cholesterol ELISAs
were performed using 5 μl of serum diluted in 45 μl of sample diluent. Serum and
standards were ran in duplicate in both triglyceride and cholesterol kits, and was
absorbance readings were taken at 450 nm. A standard curve was generated from
standards ran in each kit, and triglyceride and cholesterol concentrations were
quantified by comparing readings against the standard curve as described by the
manufacturer.
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Statistical Analysis
Comparisons of treatment groups were made using Graph Pad Prism Version
8 (GraphPad Software, Inc.). Vaginal openings and anal genital distances were
analyzed via a one-way ANOVA, with a significance set at a p value of p<0.05. Body
weights, estrus cycles, and glucose tolerance tests were analyzed using a two-way
ANOVA, with a significance set at a p value of p<0.05. Adipocyte sizes were analyzed
between groups using a one-way ANOVA with a significance set at a p value of
p<0.05. ELISA data and follicle counts were analyzed between groups using a
Student’s t-test, and with a significance set at a p value of p<0.05.

Results
DHT-treatment mimics the physiological effects of PCOS
A key feature of PCOS is hyperandrogenism, and a mouse model of PCOS can
be created through pre-pubescent introduction of androgens [14]. In order to
induce PCOS, mice were implanted with dihydrotestosterone (DHT) pellets at 23-25
days of age, and monitored for 90-days. Two non-invasive methods of analyzing
whether or not the DHT is effecting the physiology of the mice is by monitoring
vaginal opening after implantation to determine the age of puberty, and measuring
anal-genital distance (AGD) after 90 days. Exposure to hormones, such as DHT, can
cause female mice to enter puberty at an earlier age than placebo groups [17, 18].
We found that treatment of DHT, regardless of genotype, caused mice to enter
puberty significantly earlier than the placebo group. DHT-treated mice entered
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puberty early at 26 days of age on average, and placebo mice entered puberty at 36
days (Fig.1, p < 0.05). AGD was also observed to be significantly longer in the DHT
group having an average AGD of 6.7 mm compared to the placebo group, which has
an average AGD of 4.6 mm (Fig.1, p < 0.05).

Figure 1: Effects of DHT on Secondary Sex Characteristics. A) The age of puberty was
determined by observing the age when vaginal opening occurred. B) Anal genital distance
was measured at 90 days post-implantation using a digital caliper. Data shown is average ±
SEM (n = 8 for both placebo groups, n = 7 for both DHT groups). Data was analyzed using
Tukey’s multiple comparison tests between DHT and Placebo groups (*p < 0.05).

On average, mice have a four-day estrus cycle, and completing one cycle
typically correlates with oocyte release [19]. Therefore, we chose to monitor estrus
cycles as an indirect measure of fertility. Estrus cycles were monitored for a total of
14 consecutive days at 6 weeks post-implantation via daily vaginal smears to
determine which stage of the estrus cycle they were in (Fig. 2). Mice in the placebo
groups on average completed more estrus cycles in a 14-day period than mice in the
DHT groups, regardless of genotype (Fig. 3, p < 0.05).
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Figure 2: DHT-Treated Mice Have Disrupted Estrus Cycles. A-D) Examples of vaginal
washes from in diestrus (A), proestrus (B), estrus (C), and metestrus (D) phases of the
estrus cycle. E-H) Estrous cycle pattern in representative mice from wild-type placebo (E),
NAG-1 placebo (F), wild-type DHT (G), and NAG-1 DHT (H) groups. (P, Proestrus; E, Estrus;
M, Metestrus; D, Diestrus). Images were taken at 200x, and scale bars represent 200 µm.
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Figure 3: Effects of DHT on Estrus Cycles. Number of cycles completed over 14 days.
Percentage of mice to complete one estrus cycle is reported as average (n = 8 for both
placebo groups, n = 7 for both DHT groups). Tukey’s multiple comparison tests were
conducted for the comparison of estrus cycles between all groups (*p < 0.05).

After an oocyte is ovulated, a structure called a corpus luteum forms from the
ruptured follicle. The observation of a corpus lutea in the ovary signifies that the
mouse has ovulated and can be an indirect measure of normal ovarian health [20].
DHT-treatment in C57BL/6 mice has been shown to have negative impacts on
folliculogenesis, including a lack of small preantral follicle maturation, and the
formation of ovarian cysts [14]. Ovaries were collected from mice at 90 days postimplantation and the numbers of follicles at different stages of folliculogenesis were
counted. Only follicles with an oocyte present were counted, and the stage of
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folliculogenesis was determined based on the thickness of the cell layer surrounding
the oocyte. On average, mice in the placebo groups have significantly larger number
of small preantral follicles and corpus lutea than mice in the DHT group, regardless
of genotype (Fig. 4 E & F, p < 0.0001). NAG-1 DHT-treated mice were also observed
to have a significantly larger number of small antral and large antral follicles than
the NAG-1 placebo group (Fig. 4 F, p < 0.0001).
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Figure 4: Effects of DHT on Ovarian Follicles. A representative ovarian section at from
mice belonging to the wild-type placebo (A), NAG placebo (B), wild-type DHT (C), and NAG
DHT (D) groups. “CL” indicates presence of corpus lutea. E) Follicle counts of wild-type
placebo (n = 7) and DHT (n = 6) groups. F) Follicle counts of NAG placebo (n = 5) and NAG
DHT (n = 5) groups. Data shown is average ± SEM. Two tailed t-tests were conducted to
compare follicle counts between groups (*p < 0.05). Images were taken at 200x, and scale
bars represent 200 µm.
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NAG-1 Mice Are Resistant to DHT-Induced Fat Storage
C57BL/6 mice exposed to DHT-treatment have been shown to display
increased weight gain over the course of the 90-day treatment [21, 22]. In order to
examine whether NAG mice exhibited significant weight gain after DHT exposure,
we recorded body weights weekly for 90 days. NAG mice weighed significantly less
than wild-type mice, regardless of being treated with placebo or DHT pellets (Fig. 5
A & B, p < 0.05). In weeks two through nine, wild-type placebo mice weighed less
than the wild-type DHT group (Fig. 5 C, p < 0.05). There was no significant difference
among the weights of the NAG placebo and DHT-treated mice aside after the first
week post-implantation (Fig. 5 D, p < 0.05). Regardless of treatment, wild-type mice
weighed more than the NAG mice, and the wild-type-DHT mice weighed more than
the wild-type placebo group. The findings that wild-type mice weigh more than
NAG-1 mice and wild-type mice treated with DHT weight more than the wild-type
placebo group are consistent with previously published studies [11, 23].
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Figure 5: Effects of DHT and Genotype on Body Weight. Weights were recorded each
week over 90 days. Figures A and B show comparisons between genotype, and figures C and
D show comparisons between treatments. Data shown is average ± SEM (n = 8 for both
placebo groups, n = 7 for both DHT groups). Tukey’s multiple comparison tests were
conducted for the comparison of weight between all groups (*p < 0.05).

White adipose tissue stores fat in the form of lipids. Each white adipocyte is
comprised of one large lipid droplet accounting for most of the cell’s area. When
mice gain weight, they are not necessarily gaining more white adipocytes, but rather
the lipid droplets stored within the adipocytes grow larger [24]. We compared the
sizes of white adipocytes between genotypes and treatment groups to analyze
potential effects DHT on fat storage. Adipocytes were classified using the Adipocytes
Tools plugin on ImageJ into four different sizes. Small adipocytes were between 0
and 500 um2, medium adipocytes were between 500 and 1000 um2, large
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adipocytes were between 1000 and 1500 um2, and extra large were greater than
1500 um2. Representative sections from each treatment groups are shown in Figure
6. We observed NAG-1 mice trending towards having a greater number of small
adipocytes, regardless of treatment, and we also observed the NAG-1 placebo mice
having significantly fewer large and extra-large adipocytes than the wild-type
placebo group (Fig. 7) (p < 0.05). Our results indicate that DHT does not have a
significant impact on adipocyte hypertrophy, regardless of genotype. However,
white adipocyte hypertrophy is significant between wild-type and NAG-1 placebo
groups when white adipocytes are larger than 1000 um2.

Figure 6: White Adipocyte Histology After DHT-Treatment. Representative H&E stained
images of white adipocytes taken from mice belonging to the wild-type placebo (A), NAG
Placebo (B), wild-type DHT (C), and NAG DHT (D) groups. Data is representative of n = 8 for
both placebo groups, and n = 7 for both DHT groups. Images were taken at 200x
magnification, and scale bars represent 200 µm.
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Figure 7: Percentages of Cell Sizes of White Adipocytes. Cell sizes from white adipose
tissue collected from mice 90 days post-implantation. Data is shown as average ± SEM (n = 8
for both placebo groups, n = 7 for both DHT groups). Tukey’s multiple comparison tests
were conducted for the comparison of cell sizes between all groups (*p < 0.05).

Hepatic steatosis is an extreme phenotype that can be present in individuals
with PCOS. Hepatic steatosis occurs when fat deposits accumulate in the liver, which
can ultimately impact the ability of the liver to function normally [9, 25]. Hepatic
steatosis may also develop into cirrhosis or liver cancer [25]. Liver samples were
analyzed across treatment groups for the presence of adipocytes, and no visible
adipocytes or differences in liver morphology were observed across treatment or
genotype (Fig. 8). To confirm a lack of steatosis, a representative slide from each
liver sample was run on ImageJ using Watershed Algorithm package, and no white
adipocytes were detected.
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Figure 8: Liver Histology After DHT-Treatment. Representative images of liver taken
from mice belonging to the wild-type placebo (A), NAG Placebo (B), wild-type DHT (C), and
NAG DHT (D) groups. Images were taken at 200x magnification, and scale bars represent
200 µm.

Differences in Glucose Tolerance due to DHT-Treatment are Insignificant
Glucose intolerance is common in PCOS patients and is one method to
diagnose type-II diabetes [26]. To test for the presence of glucose intolerance, we
performed an intraperitoneal glucose tolerance test 13 weeks post-implantation. No
statistical significance was observed in the wild-type mice between placebo and
DHT-treated groups, but the DHT-treated group did have higher fasting glucose than
the placebo group, and did not return to a basal level in 180 minutes (Fig. 9 A).
There was no statistical significance between the NAG-1 mice placebo and DHTtreated groups. Both groups had the same fasting glucose levels and returned to
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similar basal levels by 180 minutes. Although not statistically significant, the NAG-1
DHT group had a notably smaller spike in glucose at the 20- and 40-minute mark
post-injection (Fig. 9 B) compared to the placebo treated NAG-1 mice.

Figure 9: Glucose Tolerance Tests. Mice were fasted overnight and IPGTT was performed
90 days post-implantation. Data shown is average ± SEM at each time point (n = 5 for wildtype and NAG placebo groups, n = 5 for wild-type DHT group, and n = 6 for NAG DHT
group). Data was analyzed using multiple t-tests and no significance was found.

Brown Adipose Morphology
Brown adipose tissue is highly metabolically active and thermogenic [11]. Its
abundance decreases as mice age, but is still present in small amounts in adults [27,
28]. Brown adipocytes are much smaller and compact than white adipocytes, and
are comprised of several small lipid droplets rather than one large droplet. The
brown coloration of the adipocytes is due to the abundance of mitochondria [29].
When brown adipose tissue was collected from mice at 90 days post-implantation,
we noticed no atypical morphological features in wild-type placebo, NAG-1 placebo,
and NAG-1 DHT groups (Fig. 10 A, B, & D). In the wild-type DHT group, we observed
a large amount of brown adipocytes that appeared to be storing more lipids, based
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on the increase in size of lipid droplets over any of the other groups (Fig. 10 C).
These brown adipocytes also appear to have begun to take on the appearance of
white adipocytes in certain regions. This brown adipocyte hypertrophy occurred in
the wild-type DHT-treatment group but was not observed in the transgenic NAG-1
DHT-treatment group. To further assess whether the brown adipocytes seen in the
wild-type DHT group were significantly larger than brown adipocytes in the wildtype control group, we analyzed all cells to see if they measured at or above our
smallest white adipocyte (< 90 um2) sampled in Figure 6. This area was deemed
appropriate as a threshold, as the area of brown adipocytes rarely exceeds 25 um2
[30]. We observed that the wild-type DHT group had a significantly greater number
of enlarged brown adipocytes compared to the other groups, which showed no
difference between one another (Fig. 11) (p < 0.01).

DHT Has No Effect on NAG Mice Triglyceride Levels
High triglyceride and cholesterol levels serum levels are not direct symptoms
of PCOS, but can arise as a consequence of metabolic symptoms associated with
PCOS such as glucose intolerance and type-II diabetes [31]. Cardiovascular disease
is estimated to be twice as common in women with PCOS than in the general
population, and high levels of triglycerides and cholesterol can be precursors to
cardiovascular disease [32]. We examined serum levels of triglycerides and
cholesterol to see if the DHT implantation was having an effect on circulating levels
of either. Serum was collected from mice 90 days post-implantation, and ELISAs
were performed in duplicate for both triglyceride and cholesterol levels.
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Figure 10: Brown Adipocyte Histology After DHT-Treatment. Representative images of
brown adipocytes taken from mice belonging to the wild-type placebo (A), NAG Placebo (B),
wild-type DHT (C), and NAG DHT (D) groups. Data shown is representative of n = 8 for both
placebo groups, and n = 7 for both DHT groups. Images were taken at 200x magnification,
and scale bars represent 200 µm.
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Figure 11: Enlarged Adipocytes Within Brown Adipose Tissue. Number of enlarged
adipocytes within brown adipocytes collected from mice 90 days post-implantation.
Enlarged adipocytes were defined as having an area >90 um2. Data shown is average ± SEM
(n = 8 for both placebo groups, n = 7 for both DHT groups). Student’s t-tests were conducted
for the comparison of cell sizes between all groups (**p < 0.01).

On average, NAG-1 mice have lower serum triglyceride levels than wild-type
mice, regardless of treatment group (Fig. 12 A) (.81 nmol/ml vs. 14.7 nmol/ml, p <
0.05). Both groups of DHT-treated mice trended towards having higher cholesterol
levels than the placebo groups, but no significance was observed.
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Figure 12: Serum Triglyceride and Cholesterol Levels in DHT -Treated Mice. A)
Triglyceride ELISA results from serum samples collected from mice 90 days postimplantation. B) Cholesterol ELISA results from serum samples collected from mice 90 days
post-implantation. Data shown is average ± SEM (n = 8 for both placebo groups, n = 7 for
both DHT groups). Tukey’s multiple comparison tests were conducted for the comparison of
triglyceride and cholesterols levels between all groups (*p < 0.05).

Discussion
This study was designed to examine if female transgenic NAG-1 mice were
resistant to hormonally induced metabolic disorders observed in PCOS, including
changes in body weight, adipocyte morphology, glucose intolerance, and serum
triglyceride and cholesterol levels. As a first step we determined that prolonged
DHT-treatment could induce the same physiological effects of PCOS in NAG-1 mice
as previously observed in wild-type mice. To test this, we measured age at which
mice entered puberty, AGD, estrus cycles, and ovarian follicle counts.
Our data indicate that NAG-1 mice show no difference in response to DHTtreatment when compared to wild-type mice treated with DHT in regards to
changes in the onset of puberty and AGD [17, 18]. Female mice exposed to DHT
entered puberty earlier and have increased AGD at 90 days post-implantation than
either placebo group, regardless of genotype. The responses to DHT seen in this
study align with previous research [14]. In addition, NAG-1 mice also display similar
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ovarian physiology to wild-type mice when treated with DHT. Both NAG-1 and wildtype DHT groups had disrupted estrus cycles across a two-week period, and also
completed significantly fewer cycles in comparison to the placebo groups. Both the
wild-type and NAG-1 treatment groups have decreased numbers of corpus lutea
present, which suggests anovulation [33]. Our results indicate that NAG-1
transgenic mice have a similar ovarian response to excess DHT as wild-type mice,
which is similar to physiological changes reported in PCOS [14, 21, 22]. Given that
the ovarian and reproductive phenotypes associated with PCOS are some of its
primary components, demonstrating that our DHT-induced mouse model of PCOS
still produces key reproductive phenotypes in mice was a critical first step in
confirming that PCOS is inducible in NAG-1 mice [14, 21, 22].
Body weight has been shown to increase in wild-type mice treated with DHT,
but no studies have been done on DHT-treatment in NAG-1 mice [14, 21]. NAG-1
mice appear to be resistant to hormonal-induced weight gain. We observed a
significant difference in weights across genotype, regardless of treatment, as
reported previously in NAG-1 mice [12]. There was significant difference in weights
between the wild-type groups in weeks 2-9, and again at week 12, which is similar
to previous research that has shown that DHT-induced PCOS leads to significance in
weight gain several weeks post implantation, but can taper off and lose significance
around week 7 [22]. Another study in which significant weight gain is observed
through the entirety of the study used mice fed a high-fat diet, whereas the mice in
this study were not, which may account for the loss of significance at weeks 10 and
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11 [34]. NAG-1 mice only had differing weights in the first week, which suggests that
the NAG-1 transgene may prevent hormonal induced weight gain in mice.
As the severity of weight gain increases in both humans and mice, white
adipocytes increase in size as well [35]. In our study we observed that wild-type
mice trended towards having lower amounts of small (100-500 um2) adipocytes, as
well as increased numbers of large (1000-15002) and extra large (15002+)
adipocytes. As adipocyte size has been shown to increase as a result of weight gain,
it was hypothesized that there would be differences in cell sizes between the wildtype treatment groups, but the trends were not significant [36, 37]. The lack of
significance in adipocyte size may be due to adipocytes being collected at 90 days
post implantation, when differences in weight gain began to lose significance
between wild-type groups several weeks before tissue collection. The NAG-1
placebo group had significantly less adipocytes with areas larger than 1000 μm2
than the wild-type placebo group, supporting that NAG-1 mice have leaner
phenotypes than wild-type mice. Together, the lack of weight gain observed
between NAG-1 treatment groups and the lack of alteration in white adipocyte
morphology is suggests that NAG-1 transgenic mice are resistant to DHT-induced
weight gain, and white adipocyte hypertrophy. Although we did not see a change in
white adipocyte size in the NAG-1 treatment groups, we cannot make a definitive
conclusion as to whether NAG-1 mice are resistant to excess lipid storage, as we also
observed no significant difference between the wild-type treatment groups.
Additionally, no white adipocytes were seen in liver samples in both genotypes and
treatment groups when examining liver morphology for the presence of steatosis.
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The lack of significant white adipocyte hypertrophy and steatosis may be indicative
that DHT-treatment alone is not adequate to induce profound changes in adipocyte
morphology, and the use of a high-fat diet may be necessary as well for the study of
these phenotypes [34].
NAG-1 mice display no morphological increases in adipocyte size in brown
adipose tissue when treated with DHT in contrast to wild-type mice, which had a 5fold increase in hypertrophic brown adipocytes (Fig. 11). We observed a
significantly higher number of unilocular adipocytes in the wild-type DHT group in
comparison to all other groups, which suggests that there is some conversion from
brown adipocytes to white adipocytes in response to DHT treatment, and possibly
loss of the high metabolic activity associated with brown adipocytes [38]. We
observed no difference in adipocyte morphology in the NAG-1 groups, which
suggests that DHT-treatment does not cause this observable differentiation in NAG1 mice. If brown adipocytes are differentiating into white adipocytes in wild-type
mice, this may be a contributing factor to the observed weight gain, and the lack of
adipocyte hypertrophy seen in NAG-1 mice may contribute to their ability to resist
hormonal-induced metabolic disorders. More research needs to be done to confirm
these hypotheses, but we hypothesize that analyzing gene expression of
thermogenesis-related genes (i.e. UCP1, PGC1a, Cox8B, and Dio2) in brown adipose
tissue could provide more insight, as upregulation of these genes can indicate an
increased level of thermogenesis [11].
Excess DHT has been shown to cause glucose intolerance in mice, however
we observed no significant difference in glucose tolerance between treatment
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groups [22]. Although DHT-treated wild-type mice did not have significant changes
in glucose tolerance, the results are consistent with previous research on insulin
resistance and glucose intolerance in PCOS rodent models [39]. The NAG-1 placebo
mice had a notably higher initial spike in blood glucose in response to the injection
as opposed to the NAG-1 DHT group, which may suggest a level of improved glucose
uptake in DHT-treated NAG-1 mice. The improved glucose tolerance in NAG-1 mice
is consistent with previous research [23], but the further improvement when mice
are treated with DHT is novel. The lack of significance in the wild-type groups in this
study may be attributed to the mice not being fed a high-fat diet in comparison to
similar studies [23, 34]. Additionally, the small sample size may also contribute to
the lack of significance, as other studies have between 9-12 mice [14, 21].
The combination of results regarding brown adipocyte hypertrophy and
glucose tolerance indicate that DHT may be having a more significant impact on
brown adipocyte function than on glucose intolerance, as there seems to be a
correlation between the degree of brown adipocyte hypertrophy and weight gain in
wild-type mice. This may provide insight into brown adipose tissue’s role in
regulating weight gain, and its link to NAG-1. Our results suggest that as NAG-1 is
expressed in mice, brown adipose tissue retains its normal morphology under
hyperandrogenic conditions, and may also remain highly thermogenic.
Additionally, NAG-1 mice had lower triglyceride levels than wild-type mice,
regardless of treatment groups, which is consistent with previous research on
transgenic mice [11, 40]. A lack of elevation in serum cholesterol and triglyceride
levels has been reported in DHT-treated wild-type mice, but elevated levels of
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cholesterol and triglycerides have been reported in studies using high-fat diets [21,
34, 39]. As NAG-1 mice maintain lower triglyceride levels, even when
hyperandrogenism is induced, expression of NAG-1 may play a role in reducing
triglycerides, but appears to have no impact on serum cholesterol levels. Although
increased concentrations of both triglycerides and cholesterol can predispose an
individual to cardiovascular disease, a reduction in triglycerides alone can lower the
risk of cardiovascular disease [41].
NAG-1 mice have been shown to display upregulation of thermogenesis
related genes, and so the lack of weight gain induced by DHT-treatment may be
attributed to an elevated level of thermogenesis. It appears that brown adiposemediated thermogenesis may not be impaired, as indicated by the lack of
morphological changes in brown adipose tissue in the NAG-1 DHT-treatment group.
Previous research has shown distinct difference in white adipocyte morphology in
DHT-treated mice, we conclude that the lack of significance in adipocyte size is due
to adipocytes being collected at a point in the study where the weights between
treatment groups had eclipsed one another. The lack of significance in weights
between weeks 10-12 and at week 14 in the wild-type placebo and DHT groups may
be attributed to the mice not being fed on a high-fat diet as described in previous
studies [23, 34]. The lack of significance in glucose tolerance between wild-type
groups in this study compared to similar studies may also be a result of not being
fed on high-fat diet [23, 34]. The phenotypes observed in NAG-1 mice in this study
were consistent with previous research, and we are able to conclude that NAG-1
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mice are able to maintain a lean phenotype, even when hyperandrogenism is
induced via DHT.
Women with PCOS have chronic low-level inflammation in addition to the
common ovarian and metabolic phenotypes discussed in this paper [42, 43]. As
serum levels of inflammatory cytokines, such as Tumor Necrosis Factor-alpha (TNFa), interleukin-18 (IL-18), and interleukin-6 increase (IL-6), inflammatory cytokine
levels also increase in adipose tissue [44, 45]. Increased inflammation is also linked
to insulin resistance, which is estimated to be present in 50-70% of women with
PCOS [46, 47]. Obese patients with PCOS have also been shown to have elevated
levels of the cytokine TNF-a compared to non-PCOS patients [48]. Elevated IL-18
levels have been linked to higher incidences of cardiovascular disease [49].
Together, this data suggest that inflammation plays a key role in the development of
metabolic disorders in women with PCOS. NAG-1 is secreted in direct response to
these cytokines, and while the mechanism is unclear, it appears to play a role in the
regulation of inflammatory responses through downstream activation of
transforming growth factor-beta [50]. NAG-1 is secreted as a disulfide-linked dimer
in response to cytokine release, and binds to the GFRAL receptor where it promotes
weight loss and lowers pro-inflammatory cytokine levels [50, 51]. While
inflammatory responses were not explored in this paper, we propose a model that
in addition to the increased levels of thermogenesis in NAG-1 transgenic mice, the
anti-inflammatory and anti-insulin-resistance properties of the gene may also play a
role in preventing the metabolic disorders associated with PCOS [33]. Figure 13
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describes a possible mechanism for how the overexpression of NAG-1 may reduce
inflammation and prevent hormonal induced weight gain.

Figure 13: NAG-1 and Inflammation. NAG-1 is secreted in response to an initial release of
cytokines, and functions to mediate the release of more cytokines. When the expression of
NAG-1 is initiated, it further inhibits the release of cytokines and thus reduces the chronic
inflammation in PCOS. In addition, the expression of NAG-1 also aids in preventing insulin
resistance, and may also cause downstream upregulation of thermogenesis related genes
that prevent weight gain and obesity.

In conclusion, this study explores the ovarian and metabolic phenotypes
associated with DHT-induced PCOS in NAG-1 mice. We have shown that transgenic
NAG-1 mice are resistant to hormonal induced weight gain, white and brown
adipocyte hypertrophy. In addition, NAG-1 mice also exhibit similar ovarian
phenotypes to wild-type mice when exposed to DHT (Table 1 summarizes the
features of PCOS observed between wild-type and NAG-1 mice). More research
needs to be performed on the effects of NAG-1 overexpression in response to DHT-
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treatment when mice are fed a high-fat diet, and also in regards to the chronic
inflammation associated with PCOS, but our results indicate that overexpression of
NAG-1 may be promising in preventing hormonal induced metabolic disorders.

Table 1: Summary of metabolic and ovarian phenotypes between genotypes
observed in a DHT-induced mouse model of PCOS

Treatment Groups
Phenotypes of DHT-induced PCOS
in wild-type Mice

Wild-type DHT

NAG DHT

Early onset of puberty
Increased anal-genital distance
Weight gain
Irregular estrus cycles
Glucose intolerance
Decreased corpus lutea count
White adipocyte hypertrophy
Brown adipocyte hypertrophy
Increased triglyceride levels
Increased cholesterol levels
Hepatic steatosis
✔, present; ✗, not present; *, maintained lower than wild-type
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